Back to top
more

Vanda Pharmaceuticals (VNDA)

(Delayed Data from NSDQ)

$5.32 USD

5.32
448,370

+0.05 (0.95%)

Updated Jul 9, 2024 04:00 PM ET

After-Market: $5.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AbbVie Secures FDA Approval for Endometriosis Drug Elagolix

AbbVie (ABBV) gains an FDA approval for its late-stage pipeline candidate, Orilissa, for the treatment of moderate to severe pain associated with endometriosis in women.

    Swarup Gupta headshot

    Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions

    Biotech stocks are largely resilient to trade related disruptions.

      AstraZeneca Sells Atacand's European Rights to Cheplapharm

      AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.

        Allergan's Depression Candidate Gets Fast Track Designation

        The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.

          Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label

          Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.

            Madhu Goel headshot

            4 Biotech Bets to Watch as Industry Rebounds in a Month

            The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.

              Roche's Tecentriq Gets Breakthrough Therapy Status for HCC

              The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.

                J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay

                The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.

                  Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?

                  Celgene (CELG) is likely to maintain momentum in the first quarter on the strength of its lead drug, Revlimid despite recent failures.

                    Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?

                    In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.

                      What's in the Cards for Arena (ARNA) This Earnings Season?

                      Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.

                        What's in the Cards for Ionis (IONS) This Earnings Season?

                        Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.

                          GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?

                          GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.

                            What's in Store for Intercept (ICPT) This Earnings Season?

                            Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).

                              Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?

                              Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.

                                AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?

                                AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.

                                  Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

                                  Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

                                    Tirthankar Chakraborty headshot

                                    4 Top Efficient Stocks to Buy for Stellar Returns

                                    A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.

                                      Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy?

                                      Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy?

                                        bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session

                                        bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

                                          Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice

                                          Vanda Pharmaceuticals (VNDA) stock is looking quite impressive now for momentum-oriented investors.

                                            Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR

                                            Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR

                                              Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3%

                                              Vascular Biogenics (VBLT) shares rose over 5% in the last trading session.

                                                Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%

                                                Vanda Pharmaceuticals Inc. (VNDA) shares rose over 8% in the last trading session.

                                                  Merck KGaA Expands Distribution Deal with Roche (revised)

                                                  Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).